Symptom Management and Health-Related Quality of Life Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committee (SC) was established in April 2006. The core committee membership includes representatives from the NCI Community Oncology Research Program (NCORP) Research Bases, R01 investigators, community oncologists, biostatisticians, patient advocates and NCI Staff.

Roles of the Committee

  • Evaluate and prioritize symptom management intervention clinical trial concepts, including those with primary quality-of-life (QOL) endpoints, to be conducted through the NCORP mechanism;
  • Evaluate studies with co-primary QOL endpoints in NCTN Group treatment studies;
  • Develop criteria for concepts that are eligible for proposed Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) funds.
  • Convene Clinical Trial Planning Meetings (CTPM) to identify critical questions and prioritize key strategies related to side effects of cancer, cancer treatment and patients’ quality of life.

Roster of Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committee (SC) members


2015 Symptom Management and Health-Related Quality of Life Steering Committee Strategic Priorities

SxQOL Activities

Clinical Trials Planning Meetings (CTPMs)

Videos and Webinars

Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee.

Trial IDNCT IDTrial Title
NCCTG-N08C3 NCT00880191 Phase III Double-Blind, Placebo Controlled Study of Gabapentin for the Treatment of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy
NCCTG-N08C7 NCT00956813 Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes
WFU-08-08-08 NCT00994279 Yoga during Breast Cancer Treatment: Establishing Community-Based Partnerships
HLMCC-0806 NCT01009918 Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin)
NCCTG-N08CB NCT01099449 A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity
WFU-08-03-06 NCT01032200 Phase II Randomized Placebo Controlled Study of Armodafinil on Fatigue in Brain Tumor Patients Receiving Brain Radiation Therapy
WFU-08-08-09 NCT01105130 A Randomized Phase II Dose Finding Study of ArginMax with or without Phosphodiesterase-5 Inhibitors for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy

Find all NCI-sponsored clinical trials.

CCCT Contact: Susan Rossi, Ph.D., M.P.H.